The coronavirus pandemic has been the driving force shaping the biopharma and medtech sectors over the first half of 2020. And, while much of the fallout has been predictable, certain events and trends have surprised.
Anyone thinking that 2020 might travel down a predictable path for the biopharma sector was swiftly disabused of this view in the opening weeks of the year. The coronavirus pandemic has changed the focus for almost every drug developer, whether they are working on potential treatments or trying to keep their businesses on track – or both.
Venture capital dollars flowing to US digital health continued to surge in Q3 2020. One thing is for sure—2020 will be the largest funding year ever for digital health, spurred by 24 mega deals so far.
Related Post The need for speed in the post-COVID-19 era— and h… When will the COVID-19 pandemic end? Reimagining MedTech for a COVID-19 world Digital health technology vision 2020
Survey findings confirm that organizational speed is an essential ingredient for out performance in times of unprecedented change, and point to three ways companies can gain speed for the longer term.
In 1920, a world wearied by the First World War and sickened by the 1918 flu pandemic desperately sought to move past the struggles and tragedies and start to rebuild lives. People were in search of a “return to normalcy,” as Warren G. Harding put it. Today, nearly every country finds itself in a similar position.
COVID-19 is creating unprecedented challenges for the medtech sector. Companies should consider stress-testing operating models to strengthen crisis resilience and the longer-term path to recovery.
The global pandemic has spurred a massive innovation effort from companies, governments, universities and individuals. Robots are disinfecting cities, cooking hospital food and delivering packages. Smart devices are monitoring patients’ health and collecting valuable health data.
To create a National Digital Health Eco system Support universal health coverage in an efficient, accessible, inclusive, affordable, timely and safe manner Provision data, information and infrastructure services Leverage open, interoperable, standards based digital systems Ensure security , confidentiality and privacy of health data
With this survey, we sought to understand how healthcare provider operations and needs have changed during COVID-19, and which of these changes will have long-lasting implications for how healthcare providers interact with their patients and with pharma companies.
Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies, data interoperability, and alternative employment models to prepare for these uncertainties and build a smart health ecosystem.
The increase in legal and regulatory measures arising out of COVID-19 is truly proportional to the growth of the pandemic itself. Although the measures affect all industries, many have special relevance to the healthcare and life sciences sectors. As some industries and services are forced to shut down, players in healthcare and life sciences ambit are pushed to work even harder.
The Deloitte Centre for Health Solutions, part of Deloitte UK, generates insights and thought leadership based on the key trends, challenges and opportunities within the healthcare and life sciences industry.
Few could have predicted the global events leading up to this year’s EvaluatePharma World Preview 2020. The COVID-19 pandemic has cast a long shadow over the pharmaceutical industry – which is battling to find treatments – and indeed over all the citizens of the world, who are adjusting to new ways of living and working.
The current health crisis is a wake-up call. Even in a global society that has seen significant advances in technology and healthcare, COVID-19 threatens the physical health and emotional well-being of us all.
